Fenwick & West represented Royalty Pharma in the transaction. Geron Corporation (Nasdaq: GERN) announced that Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder...
You must be a Standard 1 Year member to access this content.
Fenwick & West and Goodwin Procter represented Royalty Pharma plc in the transaction, and Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S. Ascendis Pharma A/S...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Pharmakon Advisors in the transaction. Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
You must be a Standard 1 Year member to access this content.
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Royalty Pharma, and Orrick Herrington & Sutcliffe represented Ferring Pharmaceuticals in the deal. Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals announced...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Fenwick advised Pharmakon on the deal while Akin Gump advised Pharmakon Advisors. Pharmakon, an investor in non-dilutive debt for the life sciences industry and the investment...
You must be a Standard 1 Year member to access this content.
Fenwick represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the...
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
You must be a Standard 1 Year member to access this content.
